220 related articles for article (PubMed ID: 10521169)
1. The effects of donepezil on the P300 auditory and visual cognitive evoked potentials of patients with Alzheimer's disease.
Reeves RR; Struve FA; Patrick G; Booker JG; Nave DW
Am J Geriatr Psychiatry; 1999; 7(4):349-52. PubMed ID: 10521169
[TBL] [Abstract][Full Text] [Related]
2. Distinctive Effect of Donepezil Treatment on P300 and N200 Subcomponents of Auditory Event-Related Evoked Potentials in Alzheimer Disease Patients.
Vaitkevičius A; Kaubrys G; Audronytė E
Med Sci Monit; 2015 Jul; 21():1920-7. PubMed ID: 26138001
[TBL] [Abstract][Full Text] [Related]
3. Parallel improvement of cognitive functions and P300 latency following donepezil treatment in patients with Alzheimer's disease: a case-control study.
Chang YS; Chen HL; Hsu CY; Tang SH; Liu CK
J Clin Neurophysiol; 2014 Feb; 31(1):81-5. PubMed ID: 24492450
[TBL] [Abstract][Full Text] [Related]
4. Long-term effects of donepezil on P300 auditory event-related potentials in patients with Alzheimer's disease.
Katada E; Sato K; Sawaki A; Dohi Y; Ueda R; Ojika K
J Geriatr Psychiatry Neurol; 2003 Mar; 16(1):39-43. PubMed ID: 12641372
[TBL] [Abstract][Full Text] [Related]
5. Donepezil versus vitamin E in Alzheimer's disease: Part 2: mild versus moderate-severe Alzheimer's disease.
Onofrj M; Thomas A; Luciano AL; Iacono D; Di Rollo A; D'Andreamatteo G; Di Iorio A
Clin Neuropharmacol; 2002; 25(4):207-15. PubMed ID: 12151908
[TBL] [Abstract][Full Text] [Related]
6. Donepezil, rivastigmine, and vitamin E in Alzheimer disease: a combined P300 event-related potentials/neuropsychologic evaluation over 6 months.
Thomas A; Iacono D; Bonanni L; D'Andreamatteo G; Onofrj M
Clin Neuropharmacol; 2001; 24(1):31-42. PubMed ID: 11290880
[TBL] [Abstract][Full Text] [Related]
7. P300 auditory event-related potentials and neuropsychological study during donepezil treatment in vascular dementia.
Paci C; Gobbato R; Carboni T; Sanguigni S; Santone A; Curatola L
Neurol Sci; 2006 Feb; 26(6):435-7. PubMed ID: 16601937
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of cholinergic treatment in demented patients by P300 evoked related potentials.
Werber AE; Klein C; Rabey JM
Neurol Neurochir Pol; 2001; 35 Suppl 3():37-43. PubMed ID: 12001652
[TBL] [Abstract][Full Text] [Related]
9. Effects of acute nicotine administration on cognitive event-related potentials in tacrine-treated and non-treated patients with Alzheimer's disease.
Knott V; Mohr E; Mahoney C; Engeland C; Ilivitsky V
Neuropsychobiology; 2002; 45(3):156-60. PubMed ID: 11979067
[TBL] [Abstract][Full Text] [Related]
10. Effect of donepezil on emergence of apathy in mild to moderate Alzheimer's disease.
Waldemar G; Gauthier S; Jones R; Wilkinson D; Cummings J; Lopez O; Zhang R; Xu Y; Sun Y; Knox S; Richardson S; Mackell J
Int J Geriatr Psychiatry; 2011 Feb; 26(2):150-7. PubMed ID: 20597141
[TBL] [Abstract][Full Text] [Related]
11. Effects of donepezil on Alzheimer's disease: the relationship between cognitive function and rapid eye movement sleep.
Mizuno S; Kameda A; Inagaki T; Horiguchi J
Psychiatry Clin Neurosci; 2004 Dec; 58(6):660-5. PubMed ID: 15601392
[TBL] [Abstract][Full Text] [Related]
12. Donepezil for Alzheimer's disease.
Benjamin B; Burns A
Expert Rev Neurother; 2007 Oct; 7(10):1243-9. PubMed ID: 17939763
[TBL] [Abstract][Full Text] [Related]
13. Comparative analysis of mortality in patients with Alzheimer's disease treated with donepezil and galantamine.
Capellà D; Vidal X
Age Ageing; 2007 Mar; 36(2):234; author reply 235. PubMed ID: 17255086
[No Abstract] [Full Text] [Related]
14. A comparison of donepezil and galantamine in the treatment of cognitive symptoms of Alzheimer's disease: a meta-analysis.
Harry RD; Zakzanis KK
Hum Psychopharmacol; 2005 Apr; 20(3):183-7. PubMed ID: 15700322
[TBL] [Abstract][Full Text] [Related]
15. Clinical efficacy and safety of donepezil on cognitive and global function in patients with Alzheimer's disease. A 24-week, multicenter, double-blind, placebo-controlled study in Japan. E2020 Study Group.
Homma A; Takeda M; Imai Y; Udaka F; Hasegawa K; Kameyama M; Nishimura T
Dement Geriatr Cogn Disord; 2000; 11(6):299-313. PubMed ID: 11044775
[TBL] [Abstract][Full Text] [Related]
16. Clinical benefits of a new piperidine-class AChE inhibitor.
Doody RS
Eur Neuropsychopharmacol; 1999 Apr; 9 Suppl 2():S69-77. PubMed ID: 10332937
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of donepezil in patients with more severe Alzheimer's disease: a subgroup analysis from a randomized, placebo-controlled trial.
Feldman H; Gauthier S; Hecker J; Vellas B; Xu Y; Ieni JR; Schwam EM;
Int J Geriatr Psychiatry; 2005 Jun; 20(6):559-69. PubMed ID: 15920715
[TBL] [Abstract][Full Text] [Related]
18. Donepezil for Alzheimer's disease in clinical practice--The DONALD Study. A multicenter 24-week clinical trial in Germany.
Froelich L; Gertz HJ; Heun R; Heuser I; Jendroska K; Kornhuber J; Kurz A; Mueller-Thomsen T; Ries F; Waechtler C; Metz M; Goebel C
Dement Geriatr Cogn Disord; 2004; 18(1):37-43. PubMed ID: 15084792
[TBL] [Abstract][Full Text] [Related]
19. Reviewing the role of donepezil in the treatment of Alzheimer's disease.
Doody RS; Cummings JL; Farlow MR
Curr Alzheimer Res; 2012 Sep; 9(7):773-81. PubMed ID: 22175653
[TBL] [Abstract][Full Text] [Related]
20. [Concerning the contribution by Thomas Kaiser, Christiane Florack, Heinrich Franz, Peter Sawicki: donepezil in patients with Alzheimer's dementia. The AD2000 study. Med Klin 2005;100:157-60].
Vollmar HC; Butzlaff M
Med Klin (Munich); 2005 Nov; 100(11):771; author reply 771. PubMed ID: 16328187
[No Abstract] [Full Text] [Related]
[Next] [New Search]
